Go to content

News

Filters

Changing any of the form inputs will cause the content to refresh with the filtered results.

Skip filters

Pharmacodynamic Activity, Pharmacokinetics and Tolerability of Lipid Nanoparticle Formulations of mRNA Following Repeated Intravenous Dosing in Monkeys 

Sean Semple, Vice President, Preclinical Research

American Society of Gene & Cell Therapy’s Annual General Meeting, New Orleans, LA

Read about Pharmacodynamic Activity, Pharmacokinetics and Tolerability of Lipid Nanoparticle Formulations of mRNA Following Repeated Intravenous Dosing in Monkeys 

Delivery, Potency, and Tolerability of Lipid Nanoparticle Formulations of mRNA in PXB-mice

Merete Eisenhardt, Senior Manager, Preclinical/Regulatory
American Society of Gene & Cell Therapy’s Annual General Meeting, New Orleans, LA

Read about Delivery, Potency, and Tolerability of Lipid Nanoparticle Formulations of mRNA in PXB-mice

Improved T Cell Delivery and Expression of mRNA Using CD8-Targeted Lipid Nanoparticles with Athebody® Designed Ankyrin Repeat Proteins (DARPins)

Dr. Ying Tam, Chief Scientific Officer

American Society of Gene & Cell Therapy’s Annual General Meeting, New Orleans, LA

Read about Improved T Cell Delivery and Expression of mRNA Using CD8-Targeted Lipid Nanoparticles with Athebody® Designed Ankyrin Repeat Proteins (DARPins)

Development of LNP for mRNA Cancer Immunotherapy (Presentation)

Dr. Ghania Chikh, Senior Director, Vaccine Development
World Vaccine Congress, Washington, DC

Read about Development of LNP for mRNA Cancer Immunotherapy (Presentation)

Development of LNP for mRNA Cancer Immunotherapy (Poster)

Dr. Ghania Chikh, Senior Director, Vaccine Development
World Vaccine Congress, Washington, DC

Read about Development of LNP for mRNA Cancer Immunotherapy (Poster)

Identification of Novel Lipids with Improved Activity for Prophylactic Vaccine Development

Dr. Thomas Chamberlain, Senior Research Scientist I
World Vaccine Congress, Washington, DC

Read about Identification of Novel Lipids with Improved Activity for Prophylactic Vaccine Development

Optimizing Ionizable Lipid & LNP Properties to Improve Safety

Sean Semple, Vice President, Preclinical Research

3rd LNP Immunogenicity & Toxicity Summit, Boston, MA

Read about Optimizing Ionizable Lipid & LNP Properties to Improve Safety

mRNA Therapeutics Delivery with Next Generation Ionizable Lipids

Dr. Ying Tam, Chief Scientific Officer

International mRNA Health Conference, Boston, MA

Read about mRNA Therapeutics Delivery with Next Generation Ionizable Lipids

Identification of Novel Lipids With Improved Activity for Prophylactic Vaccine Development

Dr. Ghania Chikh, Senior Director, Vaccine Development
International mRNA Health Conference, Boston, MA

Read about Identification of Novel Lipids With Improved Activity for Prophylactic Vaccine Development